Welcome to our dedicated page for KALA BIO news (Ticker: KALA), a resource for investors and traders seeking the latest updates and insights on KALA BIO stock.
KALA BIO, Inc. develops a dual strategy that combines a clinical-stage biologics pipeline for rare and severe eye diseases with an on-premises artificial intelligence infrastructure platform for biotechnology and pharmaceutical clients. Company updates cover the MSC-S platform, the KPI-012 clinical program, Researgency.ai, and the Bionic Intelligence Research Agent for secure research, clinical, regulatory, and data-workflow applications.
News also addresses capital-structure actions and corporate-status developments, including registered equity offerings, debt settlement, Nasdaq listing matters, governance changes, and the completed 1-for-50 reverse stock split of KALA common stock.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) has announced its participation in the H.C. Wainwright 24th Annual Global Investment Conference, with a pre-recorded fireside chat available from September 12, 2022, at 7:00 a.m. ET. The conference will be held virtually and in New York, NY, and management will be available for one-on-one meetings. Kala focuses on developing therapies for rare eye diseases, including its lead product candidate KPI-012 for persistent corneal epithelial defects, which has received orphan drug designation from the FDA.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced the grant of non-statutory stock options to two new employees as an inducement award under NASDAQ Listing Rule 5635(c)(4). The company granted stock options to purchase a total of 35,000 shares, with an exercise price of $0.33 per share, the closing price on August 15, 2022. The options vest over four years, with the first 25% vesting on the one-year anniversary of employment. Kala is focused on innovative therapies for rare eye diseases, with its lead candidate, KPI-012, under clinical development for persistent corneal epithelial defect.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced a dividend of one one-thousandth of a share of Series D Preferred Stock for each outstanding share of common stock, record date August 29, 2022. The Series D shares will collectively vote on a reverse stock split alongside common stockholders. Holders of these shares will not have voting rights on other matters and will be redeemed if not present at the meeting or if approved for a reverse stock split. Detailed information will be available in an upcoming Form 8-K filing.
Kala Pharmaceuticals reported a net loss of $28.1 million, or $0.38 per share, for Q2 2022, down from $36.5 million, or $0.57 per share, in Q2 2021. The net product revenues were $2.1 million, a decline from $3.1 million year-over-year. However, the company received a $60 million upfront payment from the sale of EYSUVIS and INVELTYS to Alcon Inc., allowing it to extend its cash runway into Q2 2024. A Phase 2/3 trial for KPI-012 targeting persistent corneal epithelial defect (PCED) is set to commence in Q4 2022, with topline data expected in Q1 2024.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company focused on rare eye diseases, announced its participation in two virtual healthcare investor conferences in August 2022. The first event is the Wedbush PacGrow Healthcare Conference on August 10, where company management will engage in a fireside chat at 8:00 a.m. ET. The second event is the H.C. Wainwright & Co. 2nd Annual Ophthalmology Conference on August 17, featuring a pre-recorded presentation available at 7:00 a.m. ET. Webcasts of both events can be accessed on Kala's website.
Kala Pharmaceuticals (NASDAQ: KALA) announced the grant of non-statutory stock options to a new employee, totaling 40,000 shares. This award, made as an inducement for employment outside the 2017 Equity Incentive Plan, was approved by the Compensation Committee and has an exercise price of $0.33 per share, equal to the stock's closing price on July 18, 2022. The options will vest over four years, beginning with 25% on the first anniversary and the remainder monthly thereafter. Kala is known for its innovative eye therapies, including KPI-012, targeted at rare corneal diseases.
Kala Pharmaceuticals (NASDAQ: KALA) announced the completion of its sale of a commercial portfolio, including EYSUVIS and INVELTYS, to Alcon Inc. for $60 million. This marks a strategic shift for Kala, enabling it to focus on developing KPI-012, a novel biologic for rare eye diseases. The company expects to fund operations through Q2 2024, backed by cash resources and reduced expenses. CEO Mark Iwicki emphasized the company’s strengthened financial position and commitment to advancing innovative treatments.
Kala Pharmaceuticals (NASDAQ:KALA) announced the grant of non-statutory stock options to two new employees as inducement awards outside its 2017 Equity Incentive Plan, in compliance with NASDAQ Listing Rule 5635(c)(4). A total of 50,000 shares were granted on June 15, 2022, at an exercise price of $0.39 per share. The options have a ten-year term and vest over four years. The company is focused on innovative therapies for eye diseases and is expected to finalize the sale of its commercial portfolio to Alcon Inc. in Q3 2022, pending regulatory approvals.
Kala Pharmaceuticals, Inc. (NASDAQ:KALA) announced its participation at the Jefferies Healthcare Conference in New York, scheduled for June 9, 2022. The management team will hold a fireside chat at 10:30 a.m. ET and will be available for one-on-one meetings on June 8 and 9. The company focuses on innovative eye disease therapies, utilizing its AMPPLIFY® drug delivery technology. Notably, on May 23, 2022, Kala agreed to sell its commercial portfolio to Alcon Inc., with the transaction expected to close in Q3 2022, pending regulatory conditions.
Kala Pharmaceuticals (NASDAQ: KALA) has signed a deal to sell its commercial portfolio, including EYSUVIS and INVELTYS, to Alcon Inc. for $60 million upfront, with additional sales-based milestone payments. This strategic move is aimed at focusing resources on the development of KPI-012, a therapy targeting rare ocular diseases. With this transition, Kala expects a significant reduction in operating expenses, extending its cash runway into Q2 2024. The sale is projected to close in Q3 2022, pending regulatory approvals.